4/6/2026Press ReleaseAgios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ETRead More
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on investor.agios.com
Leave the platform to read the original full article on the publisher site.
Source: Agios Pharmaceuticals
Scope: Industry
Related coverage
More related coverage
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinic...
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase...
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer
Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low...
Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
PARIS, FRANCE, 3 April 2026 — Ipsen (Euronext: IPN; ADR: IPSEY) announces that Beech Tree — which di...